volagidemab

A fully human immunoglobulin G2 (IgG2) monoclonal antibody targeting the human glucagon receptor (GCGR), that may be used for the treatment of hyperglycemia. Upon administration, volagidemab specifically targets and binds to GCGR, thereby blocking GCGR signaling. This may inhibit glucagon activity, thereby decreasing hepatic glycogenolysis and gluconeogenesis and ultimately lowering blood glucose levels. Glucagon, a hormone that increases blood sugar, plays an important role in the regulation of blood glucose levels.